The stock market performance of Sonnet BioTherapeutics Holdings Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $18.72 on 03/18/24, while the lowest price during the same time frame was $1.66, recorded on 12/05/24.
52-week price history of SONN Stock
Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Sonnet BioTherapeutics Holdings Inc’s current trading price is -83.71% away from its 52-week high, while its distance from the 52-week low is 83.67%. The stock’s price range for this period has remained between $1.66 and $18.72. The Healthcare sector company’s shares managed to surpass a trading volume of around 44.79 million for the day, which was noticeably higher compared to the shares’ average daily volume of 0.47 million over the last three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Financial Performance and Market Capitalization
Sonnet BioTherapeutics Holdings Inc (SONN) has experienced a quarterly decline of -54.09% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.14M and boasts a workforce of 12 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.28, with a change in price of -3.84. Similarly, Sonnet BioTherapeutics Holdings Inc recorded 750,710 in trading volume during the last 100 days, posting a change of -55.82%.
SONN Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for SONN stands at 0.06. Similarly, the long-term debt-to-equity ratio is also 0.03.
SONN Stock Stochastic Average
As of today, the raw stochastic average of Sonnet BioTherapeutics Holdings Inc over the last 50 days is at 16.51%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 43.26%. Further, the company’s Stochastic %K and %D values for the last 20 days were 22.66% and 10.78%, respectively.
SONN Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Year to date metric has recorded a loss of -78.10%.However, over the last six months, we can see a stronger performance of -80.65%. Over the last 30 days, the price of SONN has leaped by -17.37%. And in the last five days, it has surged by 16.82%.
